Home » Stocks » CRY

CryoLife, Inc. (CRY)

Stock Price: $30.66 USD -1.41 (-4.40%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 1.25B
Revenue (ttm) 257.89M
Net Income (ttm) -13.16M
Shares Out 38.74M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE 357.14
Dividend $0.03
Dividend Yield 0.10%
Trading Day May 7
Last Price $30.66
Previous Close $32.07
Change ($) -1.41
Change (%) -4.40%
Day's Open 31.72
Day's Range 30.48 - 32.34
Day's Volume 470,259
52-Week Range 16.13 - 32.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CryoLife (CRY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

5 days ago - Zacks Investment Research

CryoLife (CRY) delivered earnings and revenue surprises of 27.27% and 15.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 137.50% year over year to $0.03, which beat the estimate ...

1 week ago - Benzinga

ATLANTA, April 29, 2021 /PRNewswire/ -- First Quarter and Recent Business Highlights: Achieved total revenues of $71.1 million in the first quarter 2021 versus $66.4 million in the first quarter of 2020...

1 week ago - PRNewsWire

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

ATLANTA, April 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2021 financial results wi...

3 weeks ago - PRNewsWire

ATLANTA, April 7, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20th...

1 month ago - PRNewsWire

ATLANTA, March 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Oppe...

1 month ago - PRNewsWire

CryoLife (CRY) delivered earnings and revenue surprises of 1100.00% and 4.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Cryolife (NYSE:CRY) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 81.82% over the past year to $0.20, which beat the estima...

2 months ago - Benzinga

CryoLife has a resilient portfolio mix that is bolstered by upcoming regulatory catalysts. The company has decent upside potential through operations, however, this may already be reflected in valuations.

4 months ago - Seeking Alpha

ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and...

5 months ago - PRNewsWire

CryoLife's (CRY) CEO Pat Mackin on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of 1400.00% and 12.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ATLANTA, Oct. 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 third quarter financial results wil...

6 months ago - PRNewsWire

ATLANTA, Sept. 8, 2020 /PRNewswire/ -- CryoLife, Inc.

7 months ago - PRNewsWire

ATLANTA, Sept. 2, 2020 /PRNewswire/ -- CryoLife, Inc.

8 months ago - PRNewsWire

CryoLife's (CRY) CEO Pat Mackin on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of 33.33% and 4.82%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

ATLANTA, July 30, 2020 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $53.8 million in the second quarter 2020 versus $71.1 million in the second quarter of 20...

9 months ago - PRNewsWire

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

ATLANTA, July 21, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that 2020 second quarter financial results wi...

9 months ago - PRNewsWire

ATLANTA, June 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced the pricing of ...

10 months ago - PRNewsWire

CryoLife Inc. CRY, -0.72% said Thursday it is planning to offer $100 million in convertible senior notes that mature in 2024 in a private placement, joining the many companies issuing debt to bolster li...

10 months ago - Market Watch

ATLANTA, June 18, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY) ("CryoLife" or "the Company"), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it intends...

10 months ago - PRNewsWire

CryoLife, Inc. (CRY) CEO Pat Mackin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of -500.00% and 1.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

CryoLife's (CRY) On-X AAP completes the company's On-Xs heart valve portfolio.

1 year ago - Zacks Investment Research

CryoLife, Inc. (CRY) CEO Pat MacKin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of 42.86% and -4.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Figuring out bloated toxic stocks on a regular basis and discarding them at the right time is the key to successful investing.

Other stocks mentioned: BAK, ETSY, FSV, TAST
1 year ago - Zacks Investment Research

CryoLife, Inc. (CRY) CEO Pat MacKin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of 50.00% and -1.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

1 year ago - Zacks Investment Research

Overhyped toxic stocks are vulnerable to external shocks and burdened with huge amount of debt.

Other stocks mentioned: CALX, CVA, GTT
1 year ago - Zacks Investment Research

CryoLife's (CRY) CEO Pat Mackin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

CryoLife (CRY) delivered earnings and revenue surprises of 37.50% and 0.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

CryoLife's (CRY) CEO Patrick Mackin on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About CRY

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN... [Read more...]

Industry
Medical Devices
IPO Date
Feb 11, 1993
CEO
James Mackin
Employees
1,200
Stock Exchange
NYSE
Ticker Symbol
CRY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CryoLife stock is "Strong Buy." The 12-month stock price forecast is 34.58, which is an increase of 12.79% from the latest price.

Price Target
$34.58
(12.79% upside)
Analyst Consensus: Strong Buy